Addressing the hidden costs of rheumatoid arthritis
Randy Vogenberg, F.; Liebeskind, D.; Ritter, A.M.
Managed Care 14(11): 50
2005
ISSN/ISBN: 1062-3388 PMID: 16350650 Document Number: 592585
Document emailed within 1 workday
Related Documents
Tokano, Y.; Endo, S.; Hayashi, F.; Harada, S.; Kobayashi, S.; Tsuda, H.; Takasaki, Y.; Kyogoku, Y.; Arata, Y.; Okumura, K.; Hashimoto, H.; Hirose, S. 1997: A hidden immunoglobulin G2 in patients with rheumatoid arthritis detected by nuclear magnetic resonance Journal of Rheumatology 24(2): 275-281Dippell, J. 1989: Hidden IgM rheumatoid factor in chronic juvenile arthritis. An open multicenter diagnostic study Monatsschrift Kinderheilkunde: Organ der Deutschen Gesellschaft für Kinderheilkunde 137(9): 606-609
Jensen, O.H.; Danneskiold-Samsøe, B. 1985: Costs of drugs in connection with rheumatoid arthritis. Consequences of the new Danish cuts in subsidies Ugeskrift for Laeger 147(19): 1570-1572
Clarke, A.E.; St-Pierre, Y.; Joseph, L.; Penrod, J.; Sibley, J.T.; Haga, M.; Genant, H.K. 2001: Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs Journal of Rheumatology 28(11): 2416-2424
Yang, M.; Galebach, P.J.; Signorovitch, J.E.; Garg, V. 2017: Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world Clinical and Experimental Rheumatology 35(5): 791-798
Marhoffer, W.; Schatz, H.; Stracke, H.; Ullmann, J.; Schmidt, K.; Federlin, K. 1991: Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis Journal of Rheumatology 18(8): 1158-1162
Henrard, J.C.; Bennett, P.H.; Burch, T.A. 1974: Epidemiology of rheumatoid arthritis. Evaluation of the so-called Rome and new York criteria for the diagnosis of rheumatoid arthritis in a population study Revue du Rhumatisme et des Maladies Osteo-Articulaires 41(11): 675-683
Barrera, P.; Balsa, A.; Alves, H.; Westhovens, R.; Maenaut, K.; Cornélis, F.; Fritz, P.; Bardin, T.; Ceu Maia, M.; Lopes-Vaz, A.; Pascual Salcedo, D.; de la Concha, E.; Radstake, T.; van de Putte, L.B.; Migliorini, P.; Prudhomme, J.F.; Charron, D.; Spyropoulou, M.; Mendes, A.; Spaepen, M.; Martinez, M.; Stavropoulos, C. 2001: Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF) Journal of Rheumatology 28(5): 968-974
Chen, J.R.; Takahashi, M.; Suzuki, M.; Kushida, K.; Miyamoto, S.; Inoue, T. 1998: Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis Journal of Rheumatology 25(12): 2440-2444
Scherler, M. 1978: Poncet--rheumatoid arthritis. Four cases of rheumatoid arthritis treated with tuberculostatics (author's transl1 Therapeutische Umschau. Revue Therapeutique 35(3): 201-206
Korthals-de Bos, I.; Van Tulder, M.; Boers, M.; Verhoeven, A.C.; Adèr, H.J.; Bibo, J.; Boonen, A.; Van Der Linden, S. 2004: Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone Journal of Rheumatology 31(9): 1709-1716
Yamanaka, H. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. how to use the guideline in the management of rheumatoid arthritis Clinical Calcium 28(5): 607-610
Suzuki, K.; Takeuchi, T. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Towards precision medicine in rheumatoid arthritis Clinical Calcium 28(5): 626-629
Weber, R.M. 2010: Hidden tax costs of buying stock of a professional practice Journal of Medical Practice Management: Mpm 25(4): 235-239
Owen, R.; Jobling, S. 2012: Environmental science: The hidden costs of flexible fertility Nature 485(7399): 441
Singh, N.; Garg, S.C. 1988: Rheumatoid arthritis presenting as arthritis mutilans with rheumatoid lung Journal of the Indian Medical Association 86(1): 14-15
Yu, C.; Li, M.; Duan, X.; Fang, Y.; Li, Q.; Wu, R.; Liu, S.; Wang, Y.; Wu, Z.; Shi, X.; Jiang, Z.; Wang, Y.; Hsieh, E.D.; Jin, S.; Jiang, N.; Wang, Q.; Zhao, Y.; Tian, X.; Zeng, X. 2018: Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis Clinical and Experimental Rheumatology 36(5): 836-840
Lineker, S.C.; Badley, E.M.; Hughes, E.A.; Bell, M.J. 1997: Development of an instrument to measure knowledge in individuals with rheumatoid arthritis: the ACREU rheumatoid arthritis knowledge questionnaire Journal of Rheumatology 24(4): 647-653
Yasuda, S. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis Clinical Calcium 28(5): 668-676
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571